Kyntra Bio (FRA:1FG0) Cyclically Adjusted FCF per Share: €-22.35 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1FG0 Kyntra Bio Inc FRA:1FG0
51 GF Score
Price €5.70
GF Value €4.43
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Kyntra Bio Cyclically Adjusted FCF per Share?

Kyntra Bio FRA:1FG0 51 Cyclically Adjusted FCF per Share is €-22.35 as of Mar. 2026. GuruFocus rates FRA:1FG0 with a GF Score™ of 51/100 and a GF Value™ of €4.43 (Modestly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Kyntra Bio's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-2.968. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-22.35 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-03), Kyntra Bio's current stock price is €5.70. Kyntra Bio's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-22.35. Kyntra Bio's Cyclically Adjusted Price-to-FCF of today is .


Kyntra Bio  (FRA:1FG0) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Kyntra Bio Cyclically Adjusted FCF per Share Related Terms


Kyntra Bio Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Kyntra Bio's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyntra Bio Cyclically Adjusted FCF per Share Chart

Kyntra Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -21.69 -32.88 -23.33

Kyntra Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.02 -33.65 -13.70 -23.33 -22.35

FRA:1FG0 vs ACTU, PLRZ, IGC: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Kyntra Bio's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyntra Bio Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kyntra Bio's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Kyntra Bio's Cyclically Adjusted Price-to-FCF falls into.


FRA:1FG0
51GF Score
Kyntra Bio Inc FRA:1FG0
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyntra Bio Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kyntra Bio's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-2.968/330.2130*330.2130
=-2.968

Current CPI (Mar. 2026) = 330.2130.

Kyntra Bio Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 14.363 241.018 19.678
201609 -0.657 241.428 -0.899
201612 -6.993 241.432 -9.565
201703 -10.139 243.801 -13.733
201706 -6.624 244.955 -8.930
201709 -6.028 246.819 -8.065
201712 -1.205 246.524 -1.614
201803 -8.269 249.554 -10.942
201806 -9.411 251.989 -12.332
201809 1.801 252.439 2.356
201812 -5.328 251.233 -7.003
201903 5.679 254.202 7.377
201906 -7.327 256.143 -9.446
201909 -7.643 256.759 -9.830
201912 -12.054 256.974 -15.489
202003 -15.373 258.115 -19.667
202006 36.964 257.797 47.347
202009 -0.401 260.280 -0.509
202012 -2.168 260.474 -2.748
202103 -10.420 264.877 -12.990
202106 -6.351 271.696 -7.719
202109 4.048 274.310 4.873
202112 -13.440 278.802 -15.918
202203 -11.006 287.504 -12.641
202206 -8.595 296.311 -9.578
202209 -14.202 296.808 -15.800
202212 -13.264 296.797 -14.757
202303 -25.195 301.836 -27.564
202306 -26.343 305.109 -28.510
202309 -20.319 307.789 -21.799
202312 -4.322 306.746 -4.653
202403 -13.784 312.332 -14.573
202406 -9.279 314.175 -9.753
202409 -1.895 315.301 -1.985
202412 -7.244 315.605 -7.579
202503 0.619 319.799 0.639
202506 2.717 322.561 2.781
202509 -0.391 324.800 -0.398
202512 -3.869 324.054 -3.943
202603 -2.968 330.213 -2.968

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-22.35 mean?
Kyntra Bio (FRA:1FG0) has a Cyclically Adjusted FCF per Share of €-22.35 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Kyntra Bio and its competitors.
Is Kyntra Bio's Cyclically Adjusted FCF per Share too high?
Kyntra Bio's current Cyclically Adjusted FCF per Share is €-22.35. Overall, Kyntra Bio has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's Cyclically Adjusted FCF per Share compare to ACTU and PLRZ?
Kyntra Bio's Cyclically Adjusted FCF per Share of €-22.35 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Kyntra Bio and its competitors. Kyntra Bio's current Cyclically Adjusted FCF per Share is €-22.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (FRA:1FG0) is currently considered Modestly Overvalued. The stock's GF Value™ is €4.43, compared to a current price of €5.70 — trading 28.7% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-22.35. Kyntra Bio's overall GF Score™ is 51/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Kyntra Bio (FRA:1FG0), the current Cyclically Adjusted FCF per Share is €-22.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyntra Bio (FRA:1FG0) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of €5.70 is trading 28.7% above its estimated GF Value™ of €4.43. GuruFocus considers Kyntra Bio to be Modestly Overvalued.

Key valuation signals for FRA:1FG0:

  • Cyclically Adjusted FCF per Share: €-22.35
  • GF Value™: €4.43 vs. price of €5.70 (28.7% above fair value)
  • GF Score™: 51/100 with 8 warning signs

No single metric tells the full story. See the FRA:1FG0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kyntra Bio Business Description

Other Exchanges KYNB:USAKYNB:Mexico0IL8:UK
Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
51GF Score

Get the complete analysis for FRA:1FG0

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.70
Price
€4.43
GF Value